Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

The Transcriptome of Immunomodulator-Resistant Multiple Myeloma

Moritz Binder, MDMPH, S. Vincent Rajkumar, MD, Martha Q. Lacy, MD, Jessica L. Haug, Angela Dispenzieri, MD, Kimberly J. Henderson, Teresa K. Kimlinger, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 1772.

https://doi.org/10.1182/blood-2019-123407

Published: 2019

Journal Articles

Gene Expression Profiling of Structural and Functional High-Risk Multiple Myeloma

Moritz Binder, MDMPH, S. Vincent Rajkumar, MD, Martha Q. Lacy, MD, Jessica L. Haug, Angela Dispenzieri, MD, Kimberly J. Henderson, Teresa K. Kimlinger, A. Keith Stewart, MB, ChB, P. Leif Bergsagel, MD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 3061.

https://doi.org/10.1182/blood-2019-124637

Published: 2019

Journal Articles

Immunological Consequences of Lenalidomide with and without Dexamethasone in Newly Diagnosed Multiple Myeloma

Jake A. Kloeber, Teresa K. Kimlinger, Jessica L. Haug, Kimberly J. Henderson, S.Vincent Rajkumar, MD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 3070.

https://doi.org/10.1182/blood-2019-128335

Published: 2019

Journal Articles

Overcoming Resistance to Apoptosis in Multiple Myeloma By Simultaneous Inhibition of Bcl2 and IAP Families of Anti-Apoptotic Proteins

Marcus Gomez, Vijay G. Ramakrishnan, PhD, Vivek Prasad, Teresa K. Kimlinger, Utkarsh Painuly, MD, Lintao Bi, PhD, Vincent Rajkumar, MD, Shaji Kumar, MD

Blood (2014) 124 (21): 2088.

https://doi.org/10.1182/blood.V124.21.2088.2088

Published: 2014

Journal Articles

Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms

Terra Lasho, PhD, Christy Finke, BS, Teresa K. Kimlinger, Darci Zblewski, CNP, Dong Chen, MD PhD, Mrinal M. Patnaik, MBBS, Curtis A. Hanson, MD, Christopher Brooks, PhD, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD

Blood (2014) 124 (21): 5577.

https://doi.org/10.1182/blood.V124.21.5577.5577

Published: 2014

Journal Articles

Promising Pre-Clinical Activity of A-1014907, a Dual Inhibitor of Aurora Kinases and VEGFR in Multiple Myeloma

Utkarsh Painuly, MD, Vijay G. Ramakrishnan, PhD, Teresa K. Kimlinger, S. Vincent Rajkumar, MD, Shaji K. Kumar, MD

Blood (2012) 120 (21): 1848.

https://doi.org/10.1182/blood.V120.21.1848.1848

Published: 2012

Journal Articles

Simultaneous Inhibition of cIAP1, cIAP2 and XIAP Is Required for Inducing Apoptosis in Multiple Myeloma Cells.

Vijay G. Ramakrishnan, PhD, Teresa K. Kimlinger, Utkarsh Painuly, MD, Jessica Haug, S. Vincent Rajkumar, MD, Shaji K. Kumar, MD

Blood (2012) 120 (21): 2943.

https://doi.org/10.1182/blood.V120.21.2943.2943

Published: 2012

Journal Articles

Preclinical Evaluation of AT219, a Small Molecule Inhibitor of MDM2 As an Anti-Myeloma Agent.

Vijay G. Ramakrishnan, PhD, Teresa K. Kimlinger, Timothy Halling, Jessica Haug, Utkarsh Painuly, MD, S. Vincent Rajkumar, MD, Shaji K. Kumar, MD

Blood (2012) 120 (21): 2948.

https://doi.org/10.1182/blood.V120.21.2948.2948

Published: 2012

Journal Articles

Changes in Bone Marrow Plasma Cell Surface Markers Following CD138-Magnetic Bead Based Positive Selection.

Teresa K. Kimlinger, S. Vincent Rajkumar, MD, Michael P. Kline, Ph.D, Jessica L. Haug, Michael M. Timm, Thomas E. Witzig, MD, Shaji Kumar, MD

Blood (2006) 108 (11): 3516.

https://doi.org/10.1182/blood.V108.11.3516.3516

Published: 2006

Journal Articles

Mi-63, a Small Molecule Inhibitor of MDM2-p53 Interaction, Has Significant In Vitro Activity in Multiple Myeloma.

Shaji Kumar, MD, Michael Timm, Michael P. Kline, Ph.D, Jessica L. Haug, Teresa K. Kimlinger, Dajun Yang, MD, S. Vincent Rajkumar, MD

Blood (2006) 108 (11): 3464.

https://doi.org/10.1182/blood.V108.11.3464.3464

Published: 2006

Journal Articles

Epigallocatechin-3-Gallate (EGCG), a Polyphenol Extracted from Green Tea, Has Significant In Vitro Activity Against Myeloma Cells.

Shaji Kumar, MD, Michael M. Timm, Jessica L. Haug, Teresa K. Kimlinger, Linda Wellik, Michael P. Kline, Ph.D, S. Vincent Rajkumar, MD

Blood (2006) 108 (11): 3465.

https://doi.org/10.1182/blood.V108.11.3465.3465

Published: 2006

Journal Articles

Apoptosis Rates in Myeloma Cells Can Be Significantly Affected by CD138 Sorting and by the Specific Method Used To Detect Apoptotic Cells.

Teresa K. Kimlinger, BA, S. Vincent Rajkumar, MD, Michael Kline, Ph.D, Michael M. Timm, Jessica L. Haug, Thomas E. Witzig, M.D, Shaji Kumar, M.D

Blood (2006) 108 (11): 3442.

https://doi.org/10.1182/blood.V108.11.3442.3442

Published: 2006

Journal Articles

Induction of Vascular Endothelial Growth Factor (VEGF) and Interleukin 6 (IL-6) in Stromal Cells by Plasma Cells from Different Stages of Myeloma.

Jessica L. Haug, S. Vincent Rajkumar, MD, John A. Lust, MD, Thomas E. Witzig, MD, Teresa K. Kimlinger, Michael M. Timm, Michael P. Kline, Ph.D, Linda Wellik, Shaji Kumar, MD

Blood (2006) 108 (11): 5065.

https://doi.org/10.1182/blood.V108.11.5065.5065

Published: 2006

Journal Articles

Expression of CD126 (IL-R alpha) on Plasma Cells in Monoclonal Gammopathies.

Syed T. Mahmood, MD, Shaji Kumar, MD, Teresa K. Kimlinger, Jessica L. Haug, Michael Timm, Linda Wellik, Michael Kline, Ph.D, S. Vincent Rajkumar, MD

Blood (2006) 108 (11): 5066.

https://doi.org/10.1182/blood.V108.11.5066.5066

Published: 2006

Journal Articles

Expression of Cytoplasmic and Surface VEGF by Plasma Cells in Myeloma and Related Disorders.

Teresa K. Kimlinger, Thomas E. Witzig, MD, S. Vincent Rajkumar, MD

Blood (2004) 104 (11): 3655.

https://doi.org/10.1182/blood.V104.11.3655.3655

Published: 2004

Journal Articles

Expression of VEGF Receptors on Plasma Cells: Evidence of Heterogeneity.

Teresa K. Kimlinger, Thomas E. Witzig, S. Vincent Rajkumar

Blood (2004) 104 (11): 3361.

https://doi.org/10.1182/blood.V104.11.3361.3361

Published: 2004

Journal Articles

Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression

Shaji Kumar, Thomas E. Witzig, Michael Timm, Jessica Haug, Linda Wellik, Teresa K. Kimlinger, Philip R. Greipp, S. Vincent Rajkumar

Blood (2004) 104 (4): 1159–1165.

https://doi.org/10.1182/blood-2003-11-3811

Published: 2004

Journal Articles

Expression of CD52 on plasma cells in plasma cell proliferative disorders

Shaji Kumar, Teresa K. Kimlinger, John A. Lust, Kathleen Donovan, Thomas E. Witzig

Blood (2003) 102 (3): 1075–1077.

https://doi.org/10.1182/blood-2002-12-3784

Published: 2003

NARROW

The Transcriptome of Immunomodulator-Resistant Multiple Myeloma

Gene Expression Profiling of Structural and Functional High-Risk Multiple Myeloma

Immunological Consequences of Lenalidomide with and without Dexamethasone in Newly Diagnosed Multiple Myeloma

Overcoming Resistance to Apoptosis in Multiple Myeloma By Simultaneous Inhibition of Bcl2 and IAP Families of Anti-Apoptotic Proteins

Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms

Promising Pre-Clinical Activity of A-1014907, a Dual Inhibitor of Aurora Kinases and VEGFR in Multiple Myeloma

Simultaneous Inhibition of cIAP1, cIAP2 and XIAP Is Required for Inducing Apoptosis in Multiple Myeloma Cells.

Preclinical Evaluation of AT219, a Small Molecule Inhibitor of MDM2 As an Anti-Myeloma Agent.

Changes in Bone Marrow Plasma Cell Surface Markers Following CD138-Magnetic Bead Based Positive Selection.

Mi-63, a Small Molecule Inhibitor of MDM2-p53 Interaction, Has Significant In Vitro Activity in Multiple Myeloma.

Epigallocatechin-3-Gallate (EGCG), a Polyphenol Extracted from Green Tea, Has Significant In Vitro Activity Against Myeloma Cells.

Apoptosis Rates in Myeloma Cells Can Be Significantly Affected by CD138 Sorting and by the Specific Method Used To Detect Apoptotic Cells.

Induction of Vascular Endothelial Growth Factor (VEGF) and Interleukin 6 (IL-6) in Stromal Cells by Plasma Cells from Different Stages of Myeloma.

Expression of CD126 (IL-R alpha) on Plasma Cells in Monoclonal Gammopathies.

Expression of Cytoplasmic and Surface VEGF by Plasma Cells in Myeloma and Related Disorders.

Expression of VEGF Receptors on Plasma Cells: Evidence of Heterogeneity.

Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression

Expression of CD52 on plasma cells in plasma cell proliferative disorders

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only